Sept 26 (Reuters) - The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's ...

Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% dividend yield-- the highest among major drug manufacturers and one of the ...

In a report released today, Akash Tewari from Jefferies assigned a Buy rating to Pfizer (PFE – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $30.07.

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi ...

We came across a bullish thesis on Pfizer Inc. (PFE) on gurufocus by Akim Guerreiro. In this article we will summarize the bulls’ thesis on PFE. Pfizer Inc. share was trading at $29.16 as of ...

Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation ...

Pfizer is a global pharmaceutical giant with an impressive portfolio of over 350 marketed medicines, 113 experimental candidates in clinical trials, and a presence in more than 200 countries.

Pfizer and Valneva may have about two more years to wait before they make the first approval filing to the FDA for a Lyme disease vaccine, but that hasn’t stopped the companies collecting more ...

Through its Ignite program, Pfizer partners with biotechs to help them advance new drugs from preclinical development all the way to market.Ignite mainly focuses on oncology, inflammation and ...

And, of course, that also means exploring the impact of typography in branding, where fonts play an instrumental role shaping the identities of all kinds of companies, including their logos.

I view Pfizer Inc. as a leader in a defensive sector under temporary ROCE pressure. Its profit recovery and growth prospects are substantially underestimated by the prevailing market consensus.

To counter new forms of the virus, FDA approved updated vaccines from both Pfizer and Moderna last week. These new vaccines specifically target the KP.2 strain, a descendant of the Omicron variant.